Toward precision immunotherapy using multiplex immunohistochemistry and in silico methods to define the tumor immune microenvironment
Journal Title
Cancer Immunology, Immunotherapy
Publication Type
epub ahead of print
Recent developments in cancer immunotherapy promise better outcomes for cancer patients, although clinical trials for difficult to treat cancers such as malignant brain cancer present special challenges, showing little response to first generation immunotherapies. Reasons for differences in immunotherapy response in some cancer types are likely due to the nature of tumor microenvironment, which harbors multiple cell types which interact with tumor cells to establish immunosuppression. The cell types which appear to hold the key in regulating tumor immunosuppression are the tumor-infiltrating immune cells. The current standard treatment for difficult to treat cancer, including the most malignant brain cancer, glioblastoma, continues to offer a bleak outlook for patients. Immune-profiling and correlation with pathological and clinical data will lead to a deeper understanding of the tumor immune microenvironment and contribute toward the selection, optimization and development of novel precision immunotherapies. Here, we review the current understanding of the tumor microenvironmental landscape in glioblastoma with a focus on next-generation technologies including multiplex immunofluorescence and computational approaches to map the brain tumor microenvironment to decipher the role of the immune system in this lethal malignancy.
Computational deconvolution; Glioblastoma; Glioma; Immune cells; Multiplex immunohistochemistry; Tumor microenvironment
WEHI Research Division(s)
PubMed ID
Rights Notice
Refer to copyright notice on published article.

Creation Date: 2021-03-09 08:05:42
Last Modified: 2021-03-09 08:27:38
An error has occurred. This application may no longer respond until reloaded. Reload 🗙